Alison Roxby is an Infectious Disease physician affiliated with University of Washington. OpenAlex indexes 96 publications with 1,294 citations (h-index 18).
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
325 9th Ave
Seattle, WA 981042420
Telephone
206-543-4278Registry record last updated 2 Apr 2013.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Nervous system
24.6%Aminoketone4.9%Bupropion Xl80%Bupropion Hcl Sr20%Part D<11 patientsSSRI4.8%Trazodone Hcl79%Paroxetine Hcl21%Part D<11 patients+ 8 more classes in this area
Cardiovascular
22.7%Statin9%Atorvastatin Calcium83%Rosuvastatin Calcium17%Part D<11 patientsAngiotensin receptor blocker (ARB)5.2%Losartan Potassium100%Part D<11 patients+ 6 more classes in this area
Anti-infectives
20.7%Human Immunodeficiency Virus Integrase Strand Transfer Inhibitor13.6%Dovato79%Tivicay21%Part D<11 patientsHuman Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor2.9%Descovy100%Part D<11 patients+ 4 more classes in this area
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
5 NIH research awards on record, funded 2012–2026 per NIH RePORTER. The latest:
- Annual HVTN Translational HIV Early Stage Investigator (ESI) Conference
Fred Hutchinson Cancer Center
FY2026$74,999R13OD024033 - Annual HVTN Translational HIV Early Stage Investigator (ESI) Conference
Fred Hutchinson Cancer Center
FY2025$74,999R13OD024033 - Annual HVTN Translational HIV Early Stage Investigator (ESI) Conference
Fred Hutchinson Cancer Center
FY2024$74,999R13OD024033
Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.
Similar KOLs
Other experts from the same institution or the same specialty.
Rainer Storb
University of Washington
Connie Celum, MD, MPH
University of Washington
Helen Chu, MD, MPH
University of Washington
Bryan Kestenbaum, MD
University of Washington
Thomas Walsh, MD
Cornell University
Vance Fowler, MD
Duke University
Myron Cohen, MD
University of North Carolina at Chapel Hill School of Medicine
Derrick W. Crook
John Radcliffe Hospital
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments, shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”